UNSPSC 51392801: Bemoradan

This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2S2V1ETBQ, chemically known as 7-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2h-1,4-benzoxazin-3(4h)-one but generally known as bemoradan, which bears US NIH Compound Identifier 5362399. European Medicines Agency schedules Bemoradan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05695MIG. The term BEMORADAN is an International Non-Proprietary Name.

UNSPSC 51392801 Bemoradan, a Commodity code, covers pharmaceutical products and medical supplies that state and local governments procure to support community health and emergency-response initiatives. Recent solicitations under this code show purchasing of naloxone and drug deactivation systems—products used in overdose prevention and substance-abuse harm-reduction programs. Issuing bodies soliciting under the code include county health departments and community health agencies. The procurement typically requires vendors to meet standard compliance requirements, including drug-free workplace certification, E-Verify authorization, insurance coverage (workers' compensation and commercial general liability), and potential FEMA-related federal regulatory adherence.

Seminole County, Florida posted an IFB (Invitation for Bid) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2023. The contract included an initial two-year term with a one-year renewal option, and vendors were required to submit unit costs for each line item with all shipping and delivery costs included in their bids. The source provides limited visibility into geographic spread beyond Florida, with no additional recent opportunities documented under this code.